Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: Implications for multiple myeloma progression

Virginia M Shapiro, Marianne Newton Mollenauer, Arthur Weiss

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

CD28 is the major costimulatory molecule on T cells. CD28 activation, in conjunction with T-cell receptor engagement, upregulates transcription of several cytokines, including interleukin-2 (IL-2), through transcriptional activation of the RE/AP composite element. Although CD28 is not normally expressed on B cells or plasma cells, more than 90% of extramedullary myelomas (a late stage B-cell neoplasm) express CD28. The functional significance of this is unknown. The results of this study demonstrate that CD28 stimulates transcriptional activation of RE/AP-based reporters in B cells and myeloma cells. However, CD28 stimulation does not up-regulate IL-2 production in myeloma cell lines, demonstrating that the IL-2 promoter may not be a relevant RE/AP-containing target of CD28 in myelomas. Instead, an RE/AP composite element has been identified within the promoter of the IL-8 gene, a chemokine that promotes angiogenesis. Furthermore, stimulation of endogenous CD28 expressed by 3 myeloma cell lines increased IL-8 production. Therefore, the study demonstrates that CD28 is functional in myelomas to up-regulate transcription of endogenous genes, including IL-8. The proposal is made that aberrant expression of CD28 may play a role in the progression of multiple myeloma.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalBlood
Volume98
Issue number1
DOIs
StatePublished - Jul 1 2001
Externally publishedYes

Fingerprint

Multiple Myeloma
Interleukin-8
Interleukin-2
B-Lymphocytes
Up-Regulation
Cells
Transcriptional Activation
Chemical activation
Cell Line
Transcription
T-Cell Antigen Receptor
Plasma Cells
Chemokines
Genes
T-cells
Cytokines
T-Lymphocytes
Composite materials
Neoplasms
Plasmas

ASJC Scopus subject areas

  • Hematology

Cite this

Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production : Implications for multiple myeloma progression. / Shapiro, Virginia M; Mollenauer, Marianne Newton; Weiss, Arthur.

In: Blood, Vol. 98, No. 1, 01.07.2001, p. 187-193.

Research output: Contribution to journalArticle

@article{e773bf4a41dd4628b3fe227bfcf41766,
title = "Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: Implications for multiple myeloma progression",
abstract = "CD28 is the major costimulatory molecule on T cells. CD28 activation, in conjunction with T-cell receptor engagement, upregulates transcription of several cytokines, including interleukin-2 (IL-2), through transcriptional activation of the RE/AP composite element. Although CD28 is not normally expressed on B cells or plasma cells, more than 90{\%} of extramedullary myelomas (a late stage B-cell neoplasm) express CD28. The functional significance of this is unknown. The results of this study demonstrate that CD28 stimulates transcriptional activation of RE/AP-based reporters in B cells and myeloma cells. However, CD28 stimulation does not up-regulate IL-2 production in myeloma cell lines, demonstrating that the IL-2 promoter may not be a relevant RE/AP-containing target of CD28 in myelomas. Instead, an RE/AP composite element has been identified within the promoter of the IL-8 gene, a chemokine that promotes angiogenesis. Furthermore, stimulation of endogenous CD28 expressed by 3 myeloma cell lines increased IL-8 production. Therefore, the study demonstrates that CD28 is functional in myelomas to up-regulate transcription of endogenous genes, including IL-8. The proposal is made that aberrant expression of CD28 may play a role in the progression of multiple myeloma.",
author = "Shapiro, {Virginia M} and Mollenauer, {Marianne Newton} and Arthur Weiss",
year = "2001",
month = "7",
day = "1",
doi = "10.1182/blood.V98.1.187",
language = "English (US)",
volume = "98",
pages = "187--193",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production

T2 - Implications for multiple myeloma progression

AU - Shapiro, Virginia M

AU - Mollenauer, Marianne Newton

AU - Weiss, Arthur

PY - 2001/7/1

Y1 - 2001/7/1

N2 - CD28 is the major costimulatory molecule on T cells. CD28 activation, in conjunction with T-cell receptor engagement, upregulates transcription of several cytokines, including interleukin-2 (IL-2), through transcriptional activation of the RE/AP composite element. Although CD28 is not normally expressed on B cells or plasma cells, more than 90% of extramedullary myelomas (a late stage B-cell neoplasm) express CD28. The functional significance of this is unknown. The results of this study demonstrate that CD28 stimulates transcriptional activation of RE/AP-based reporters in B cells and myeloma cells. However, CD28 stimulation does not up-regulate IL-2 production in myeloma cell lines, demonstrating that the IL-2 promoter may not be a relevant RE/AP-containing target of CD28 in myelomas. Instead, an RE/AP composite element has been identified within the promoter of the IL-8 gene, a chemokine that promotes angiogenesis. Furthermore, stimulation of endogenous CD28 expressed by 3 myeloma cell lines increased IL-8 production. Therefore, the study demonstrates that CD28 is functional in myelomas to up-regulate transcription of endogenous genes, including IL-8. The proposal is made that aberrant expression of CD28 may play a role in the progression of multiple myeloma.

AB - CD28 is the major costimulatory molecule on T cells. CD28 activation, in conjunction with T-cell receptor engagement, upregulates transcription of several cytokines, including interleukin-2 (IL-2), through transcriptional activation of the RE/AP composite element. Although CD28 is not normally expressed on B cells or plasma cells, more than 90% of extramedullary myelomas (a late stage B-cell neoplasm) express CD28. The functional significance of this is unknown. The results of this study demonstrate that CD28 stimulates transcriptional activation of RE/AP-based reporters in B cells and myeloma cells. However, CD28 stimulation does not up-regulate IL-2 production in myeloma cell lines, demonstrating that the IL-2 promoter may not be a relevant RE/AP-containing target of CD28 in myelomas. Instead, an RE/AP composite element has been identified within the promoter of the IL-8 gene, a chemokine that promotes angiogenesis. Furthermore, stimulation of endogenous CD28 expressed by 3 myeloma cell lines increased IL-8 production. Therefore, the study demonstrates that CD28 is functional in myelomas to up-regulate transcription of endogenous genes, including IL-8. The proposal is made that aberrant expression of CD28 may play a role in the progression of multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0035412380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035412380&partnerID=8YFLogxK

U2 - 10.1182/blood.V98.1.187

DO - 10.1182/blood.V98.1.187

M3 - Article

C2 - 11418479

AN - SCOPUS:0035412380

VL - 98

SP - 187

EP - 193

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -